Home  |  Contact
Due to maintenance work, this service and ftp://ftp.expasy.org will be unavailable from Tuesday August 23rd 18:00 until Wednesday August 24th 08:00 CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot Q15833: Variant p.Pro477Leu

Syntaxin-binding protein 2
Gene: STXBP2
Variant information

Variant position:  477
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Proline (P) to Leucine (L) at position 477 (P477L, p.Pro477Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In FHL5; leads to a complete loss of the ability to interact with STX11.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  477
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  593
The length of the canonical sequence.

Location on the sequence:   SSRLEPRERMEPTYQLSRWT  P VIKDVMEDAVEDRLDRNLWP
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SSRLEPRERMEPTYQLSRWTPVIKDVMEDAVEDRLDRNLWP

                              SSRLERRERLEPTYQLSRWTPVIKDVMEDAVEDRLDRKLWP

Mouse                         SSRLERRERMEPTYQLSRWSPVIKDVMEDVVEDRLDRKLWP

Rat                           SSRLERRERMEPTYQLSRWSPVIKDVMEDVVEDRLDRKLWP

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 593 Syntaxin-binding protein 2


Literature citations

Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11.
zur Stadt U.; Rohr J.; Seifert W.; Koch F.; Grieve S.; Pagel J.; Strauss J.; Kasper B.; Nuernberg G.; Becker C.; Maul-Pavicic A.; Beutel K.; Janka G.; Griffiths G.; Ehl S.; Hennies H.C.;
Am. J. Hum. Genet. 85:482-492(2009)
Cited for: FUNCTION; INTERACTION WITH STX11; VARIANTS FHL5 PRO-209; ILE-232 DEL; HIS-292; TRP-405; GLN-405 AND LEU-477; CHARACTERIZATION OF VARIANTS FHL5 ILE-232 DEL; HIS-292; TRP-405; GLN-405 AND LEU-477;

Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells.
Cote M.; Menager M.M.; Burgess A.; Mahlaoui N.; Picard C.; Schaffner C.; Al-Manjomi F.; Al-Harbi M.; Alangari A.; Le Deist F.; Gennery A.R.; Prince N.; Cariou A.; Nitschke P.; Blank U.; El-Ghazali G.; Menasche G.; Latour S.; Fischer A.; de Saint Basile G.;
J. Clin. Invest. 119:3765-3773(2009)
Cited for: FUNCTION; INTERACTION WITH STX11; VARIANT FHL5 LEU-477;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.